
In summary, evidence is presented associating typically asymptomatic and reversible elevations of serum transaminase values with high daily dosages of naltrexone. Statistical significance was found only between placebo and the 300 mg dosage. Subjects aged 40 years and over were significantly more likely to develop this finding than younger subjects. All subjects with significant elevations of transaminase values in these studies took daily naltrexone dosages higher than recommended for opioid addiction. The daily dosage of naltrexone recommended for opioid addiction did not cause abnormalities of serum transaminase values in these studies.
Adult, Clinical Trials as Topic, Dose-Response Relationship, Drug, Alanine Transaminase, Middle Aged, Naltrexone, Random Allocation, Double-Blind Method, Liver Function Tests, Humans, Dementia, Aspartate Aminotransferases, Obesity, Aged
Adult, Clinical Trials as Topic, Dose-Response Relationship, Drug, Alanine Transaminase, Middle Aged, Naltrexone, Random Allocation, Double-Blind Method, Liver Function Tests, Humans, Dementia, Aspartate Aminotransferases, Obesity, Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 46 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
